Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Hereditary Angioedema
100%
C1 Inhibitor
100%
Prophylactic Treatment
100%
Sahara
100%
C1 Inhibitor Deficiency
100%
Fixed Dose
100%
Placebo
87%
Plasma-derived
75%
Number of Attacks
62%
Angioedema Attack
25%
Severe Attack
25%
Safety Profile
12%
Crossover Design
12%
Least Mean Square
12%
Submucosal
12%
Efficacy Endpoint
12%
Adverse Event Rates
12%
Hereditary Angioedema with Normal C1 Inhibitor
12%
Efficacy Safety
12%
Treatment-related Adverse Events
12%
Prescreening
12%
Car-Free Day
12%
Nursing and Health Professions
Subcutaneous Injection
100%
Placebo
100%
Angioneurotic Edema
100%
Complement Component C1s Inhibitor
100%
Isoniazid
85%
Accident Prevention
42%
Efficacy
28%
Adverse Event
14%
Least Squares Method
14%
Medicine and Dentistry
Subcutaneous Injection
100%
Placebo
100%
Hereditary Angioedema
100%
Complement Component C1s Inhibitor
100%
Isoniazid
85%
Adverse Event
14%
Least Squares Method
14%
Pharmacology, Toxicology and Pharmaceutical Science
Subcutaneous Injection
100%
Placebo
100%
Angioneurotic Edema
100%
Complement Component C1s Inhibitor
100%
Isoniazid
85%
Adverse Event
14%
Immunology and Microbiology
Blood Plasma
100%
Hereditary Angioedema
100%
C1-Inhibitor
100%